Feb 13 (Reuters) - Blueprint Medicines Q4 product revenue USD 144.125 million.
- Q4 EPS USD -0.79 vs. IBES estimate USD -0.7
- Q4 pretax profit USD -49.284 million vs. IBES estimate USD -44.5 million
- Q4 operating expenses USD 187.569 million
Feb 13 (Reuters) - Blueprint Medicines Q4 product revenue USD 144.125 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.